AFP and bone metastasis: Because lung and/or bone metastasis significantly predicted PFS in univariate analysis (P = 0.001), it was entered into multivariate analysis, adjusting other significant covariates such as S-LRTs, Child-Pugh class, tumor size, AFP level ≥400 ng/mL, PIVKA level ≥1,000 AU/L, and the cumulative dose of sorafenib.